China Biologic Products Holdings, Inc. (CBPO) Analysts See $1.11 EPS

January 21, 2018 - By Kurt Siggers

 China Biologic Products Holdings, Inc. (CBPO) Analysts See $1.11 EPS
Investors sentiment decreased to 0.03 in Q3 2017. Its down 0.62, from 0.65 in 2017Q2. It is negative, as 88 investors sold China Biologic Products Holdings, Inc. shares while 1 reduced holdings. 0 funds opened positions while 3 raised stakes. 1.23 million shares or 91.95% less from 15.29 million shares in 2017Q2 were reported.
Schroder, Maine-based fund reported 1.02 million shares. Pub Employees Retirement System Of Ohio holds 0.01% or 10,948 shares. Jupiter Asset Limited reported 0.51% stake. Matthews Int Cap Mngmt Ltd Llc reported 41,400 shares.

Analysts expect China Biologic Products Holdings, Inc. (NASDAQ:CBPO) to report $1.11 EPS on February, 22.They anticipate $0.40 EPS change or 56.34 % from last quarter’s $0.71 EPS. CBPO’s profit would be $30.64 million giving it 18.34 P/E if the $1.11 EPS is correct. After having $1.11 EPS previously, China Biologic Products Holdings, Inc.’s analysts see 0.00 % EPS growth. The stock increased 1.14% or $0.92 during the last trading session, reaching $81.43. About 103,447 shares traded. China Biologic Products Holdings, Inc. (NASDAQ:CBPO) has declined 1.48% since January 21, 2017 and is downtrending. It has underperformed by 18.18% the S&P500.

China Biologic Products Holdings, Inc. (NASDAQ:CBPO) Ratings Coverage

Among 2 analysts covering China Biologic Products (NASDAQ:CBPO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. China Biologic Products had 6 analyst reports since September 4, 2015 according to SRatingsIntel. The stock has “Buy” rating by Jefferies on Friday, October 13. The company was maintained on Thursday, August 3 by Jefferies. Jefferies maintained the shares of CBPO in report on Monday, June 12 with “Buy” rating. The rating was maintained by Jefferies with “Buy” on Tuesday, September 12. Jefferies maintained the shares of CBPO in report on Friday, September 4 with “Buy” rating.

China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. The company has market cap of $2.25 billion. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. It has a 20.65 P/E ratio. The firm also provides human immunoglobulin and immunoglobulin for intravenous injection products for original and secondary immunoglobulin deficiency, and auto-immune deficiency diseases; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus.

More notable recent China Biologic Products Holdings, Inc. (NASDAQ:CBPO) news were published by: Seekingalpha.com which released: “China Biologic Products’ (CBPO) CEO David Gao on Q2 2017 Results – Earnings …” on August 06, 2017, also Prnewswire.com with their article: “China Biologic Announces Effectiveness of Registration Statement and Mailing …” published on May 19, 2017, Nasdaq.com published: “New Silk Road Investment Pte Ltd Buys China Biologic Products Holdings Inc …” on October 18, 2017. More interesting news about China Biologic Products Holdings, Inc. (NASDAQ:CBPO) were released by: Prnewswire.com and their article: “China Biologic Announces Corporate Update” published on January 08, 2018 as well as Streetinsider.com‘s news article titled: “China Biologic Products (CBPO) Reports Acquisition of TianXinFu from PW …” with publication date: October 12, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: